Loading company…
Parallel Biosystems combines human immune organoids, AI, and robotics for drug discovery and development.
Founded in 2021 and based in Massachusetts, US, Parallel Biosystems develops human immune system models for drug discovery and development. Its platform combines immune organoids, AI, and robotics to study cells and molecules involved in health and disease. In June 2025, it raised USD 21 million in Series A funding led by AIX Ventures, with Amplo, Metaplanet Holdings, Susa Ventures, Atypical Ventures, Undeterred Capital, and individual investors participating. The funding supports its technology, team, and pharmaceutical partnerships.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in